Markets:

Overview

News

Currencies

International

Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

6.220 -0.150 (-2.35%)

Streaming Delayed Price Updated: 9:53 AM EST, Feb 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2

...

24 25 26 27 28 29 30 31 Next >

Can Psychedelics Actually Cure Depression and PTSD? ↗

May 25, 2021

There is now data suggesting that magic mushrooms and ecstasy -- combined with talk therapy -- may help people with severe depression and post-traumatic stress disorder.

Via The Motley Fool

Topics Cannabis

Psychedelic Drug Developer Sets Sights On This Age-Old Hallucinogen ↗

May 20, 2021

MindMed stock fell after it said a Swiss ethics committee cleared it to begin a study on the effects of the hallucinogen mescaline.

Via Investor's Business Daily

Compass Pathways Offers Chance on Exploratory Mental Health Treatments ↗

May 18, 2021

Over the past year, CMPS stock has been going nowhere fast. However, there's been recent progress in advancing psilocybin-assisted therapy.

Via InvestorPlace

Psyched: MindMed And Compass Q1 Earnings, FDA Approves Therapists Taking MDMA, Wesana Health Goes Public ↗

May 17, 2021

Two of the most prominent companies in the psychedelics space released their financials for the first quarter of 2021. Compass Pa...

Via Benzinga

Compass Releases Q1 Earnings: Strong Cash Position For Psilocybin R&D Efforts ↗

May 14, 2021

Compass Pathways (NASDAQ:CMPS), a company researching psyc...

Via Benzinga

How This Psychedelic Company Could Lead A Turnaround For The Sector ↗

April 10, 2021

Compass Pathways PLC (NASDAQ:CMPS) is often viewed as the leader in the psychedeli...

Via Benzinga

COMPASS Pathways plc (CMPS) Q1 2021 Earnings Call Transcript ↗

May 13, 2021

CMPS earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

Psychedelics Move to The Forefront of Innovative Research as the FDA Approves Large-Scale Testing

May 13, 2021

Via FinancialNewsMedia

Cannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week ↗

May 11, 2021

Welcome to the Cannabis Countdo...

Via Benzinga

Topics Cannabis

Why Smaller Psychedelics Companies Should Start Catching Up To The Sector Leaders ↗

May 05, 2021

Concentration of ownership in psychedelic drug stocks has reached a new extreme. We explain how and why we don't see this trend as being sustainable.

Via Talk Markets

The Next Psychedelic Stock To Uplist On The Nasdaq? ↗

May 04, 2021

As MindMed Inc makes its long-awaited move to the Nasdaq, the obvious question is: who's next?

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2021 ↗

May 11, 2021

Upgrades For CEVA Inc (NASDAQ:CEVA), Barclays upgraded the previous rating of Equal-Weight to Overweight. For the first quarter, CEVA had an EPS of $0.01, compared to year...

Via Benzinga

Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week ↗

May 04, 2021

Cannabis Countdown: Top 10 Marijuana and Psychedelic Stock News Stories of the Week

Via Benzinga

Topics Cannabis

Why Companies Are Betting Big On Psychedelic Drugs To Treat Mental Health Epidemic

April 28, 2021

Via FinancialNewsMedia

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 28, 2021

Gainers Akari Therapeutics (NASDAQ:AKTX) stock moved upwards by 14.1% to $2.67 during Wednesday's pre-market session. The company's market cap stands at $102.7...

Via Benzinga

Second-Chance Buying Opportunity With Psychedelic Stock Warrants ↗

April 27, 2021

Psychedelic stock warrants delivered epic returns for investors in the big rally in these stocks in 2020. After the pullback in 2021, some of these warrants are again looking attractive.

Via Talk Markets

MindMed Stock Climbs In Nasdaq Debut As Psychedelics Follow Pot's Path To Mainstream ↗

April 27, 2021

MindMed stock rose in its Nasdaq listing debut on Tuesday, making it the latest psychedelic drug developer to land on a major U.S. exchange.

Via Investor's Business Daily

Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week ↗

April 27, 2021

Cannabis Countdown: Top 10 Marijuana and Psychedelic Stock News Stories of the Week

Via Benzinga

Topics Cannabis

Majority Of Pure-Play Psychedelic Drug Stocks Went Up Last Week ↗

April 26, 2021

41 psychedelic drug stocks trade on the various North American stock exchanges and in the past week 24 went up, 12 went down and 5 had no change in price.

Via Talk Markets

Psyched: MindMed, Atai Head For Nasdaq, Psychedelics Search Platforms Grow, Champignon Brands Resumes Trading ↗

April 26, 2021

Two of the most highly funded companies in the psychedelics space announced plans last week to list on the Nasdaq exchange. Months after ...

Via Benzinga

With Number Of Depression Cases Rising, Psilocybin Medicines Are Being Rapidly Accepted

April 22, 2021

Via FinancialNewsMedia

Déjà Vu: 2021 Slump In Psychedelic Stocks Mirrors 2020 ↗

April 21, 2021

Charts for most psychedelic drug stocks look terrible in recent weeks. The same was true in the summer of 2020 -- immediately before these stocks exploded higher. Deja vu?

Via Talk Markets

Psychedelic Stocks: Atai Life Sciences IPO Seeks To Raise $100 Million ↗

April 21, 2021

Atai Life Sciences hopes to raise $100 million in an initial public offering, as other psychedelic stocks seek investor cash.

Via Investor's Business Daily

Topics Initial Public Offering

Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week, 4/20/2021 ↗

April 20, 2021

Welcome to the Cannabis...

Via Benzinga

Topics Cannabis

Psyched: California Psychedelics Bill Passes Second Committee, GH Research Closes $125M Series B, Study Shows Psilocybin Could Equal SSRI Results In Depression ↗

April 19, 2021

A bill that would remove penalties for the possession, personal use and social sharing of certain natural and synthetic psychedelics in Califo...

Via Benzinga

Pure-Play Psychedelic Drug Stocks Index Declined 5.7% This Week ↗

April 17, 2021

In the past week, of the 41 psychedelic drug stocks that trade on the various North American stock exchanges only nine went up, in price while 31 went down and one had no change.

Via Talk Markets

The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split ↗

April 15, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14) 10x Genomics, Inc. (NASDAQ...

Via Benzinga

Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week ↗

April 13, 2021

Welcome to the Cannabis...

Via Benzinga

Topics Cannabis

Biotech Companies Driving Psychedelics Industry Forward with Key Research

April 13, 2021

Via FinancialNewsMedia

Psychedelic Stocks Primed For Atai-MindMed Bounce ↗

April 08, 2021

It's now looking like the atai Life Sciences IPO and the MindMed uplisting to the Nasdaq could occur within weeks of each other. We point out what that means for investors in psychedelic stocks.

Via Talk Markets

Topics Initial Public Offering

< Previous 1 2

...

24 25 26 27 28 29 30 31 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.